Immutep Aces Phase IIb in First-Line Head and Neck Cancer, Eyes Regulatory Path Ahead

Immutep on Friday posted data from its ongoing Phase IIb TACTI-003 trial, demonstrating that its investigational LAG-3 therapy eftilagimod alfa elicited high response rates when used with Merck’s Keytruda for the first-line treatment of patients with metastatic head and neck squamous cell carcinoma.